

Application No. 10/680,459

Docket No.: NY-HUBR 1230-US

AMENDMENTS TO THE CLAIMS

RECEIVED  
CENTRAL FAX CENTER

DEC 03 2007

Claims 1-11. (Canceled)

Claim 12. (Currently amended) A method for treating idiopathic epilepsy in a dog, said idiopathic epilepsy being characterized by excessive transient paroxysmal neuronal discharge in the cerebral cortex of said dog, when no underlying cause can be found via clinical and pathological examination, comprising administering an amount of 1-(4-chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one or a physiological salt thereof, to a dog with idiopathic epilepsy, in an amount sufficient to alleviate said idiopathic epilepsy.

Claim 13. (Previously presented) The method of claim 12, comprising administering said 1-(4-chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one orally.

Claim 14. (Previously presented) The method of claim 12, comprising administering said 1-(4-chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one from 1-5 times per day.

Claim 15. (Previously presented) The method of claim 12, comprising administering from about 1mg to about 200 mg per kilogram of body weight of said dog of 1-(4-chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one daily.

Claim 16. (Previously presented) The method of claim 12, further comprising coadministering at least one other active ingredient.

Application No. 10/680,459

Docket No.: NY-HUBR 1230-US

Claim 17. (Previously presented) The method of claim 16, wherein said at least one other active ingredient is selected from the group consisting of Phenobarbital, primidone, and potassium bromide.

Claim 18. (Cancelled).

Claim 19. (Previously presented) The method of claim 12, wherein said idiopathic epilepsy is newly diagnosed.

Claims 20-21. (Canceled)